Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating and curing disease or repairing damaged tissues, such as bone, muscle, or nerves. At this size scale – about 500 nanometers or less –biological molecules and structures operate inside living cells. The pharmaceutical industry continues to evaluate the potential of these new technologies to alleviate the burden of rising research costs, improve the speed and efficiency of the discovery process, and create high-value new generation therapeutics. While nanotechnology is widely seen as having huge potential, the pharmaceutical industry remains skeptical that success at the bench scale can successfully be translated into high volume products.

Liquidia's PRINT® technology (Particle Replication in Non-Wetting Templates) is one example of a breakthrough in micro- and nanoparticle manufacturing that allows complete control over particle size, shape and chemical composition. Since its inception, Liquidia has been addressing nanoparticle manufacturing scale-up by adapting the PRINT particle fabrication process to merge the high-volume production methodologies of roll-to-roll processing and the high precision fabrication methods of the microelectronics industry. Using PRINT technology, Liquidia has the ability to rapidly scale up cGMP manufacturing of particles with unprecedented control over the composition and geometry. This creates the unique ability to manufacture high volumes of complex micro- and nanostructured objects in a number of particle geometries and a variety of materials in a cost paradigm that is very attractive. Using manufacturing methodologies developed and proven in other industries including the printing, film and medical device industries, Liquidia plans to scale its particle manufacturing capabilities to supply commercial quantities for a variety of industries, including diagnostics, vaccines and therapeutics.